LABORATORY RESEARCH Hematopoietic Progenitor Kinase 1 (HPK1) Is Required for Lymphocyte Function-Associated Antigen 1-Mediated Neutrophil Recruitment during the Acute Inflammatory Response Investigators showed that mammalian actin-binding protein 1 constitutively co-immunoprecipitated with hematopoietic progenitor kinase 1 in neutrophil-like differentiated HL-60 cells. [Blood] Abstract The Eukaryotic Translation Initiation Factor eIF4E Is a Direct Transcriptional Target of NF-κB and Is Aberrantly Regulated in Acute Myeloid Leukemia In primary acute myeloid leukemia (AML) specimens, generally scientists observed that substantially more NF-κB complexes associate with eIF4E promoter elements in M4 and M5 AML specimens examined than in other subtypes or unstimulated normal primary hematopoietic cells. [Leukemia] Abstract Aberrant Mer Receptor Tyrosine Kinase Expression Contributes to Leukemogenesis in Acute Myeloid Leukemia Researchers found that Mer receptor tyrosine kinase was over-expressed in a majority of pediatric and adult primary acute myeloid leukemia patient blasts at the time of diagnosis, and 100% of patient samples at the time of relapse. [Oncogene] Full Article | Press Release Potential Contribution of a Novel Tax Epitope-Specific CD4+ T Cells to Graft-versus-Tax Effect in Adult T Cell Leukemia Patients after Allogeneic Hematopoietic Stem Cell Transplantation Scientists showed that Tax-specific CD4+ as well as CD8+ T cell responses were induced in some adult T cell leukemia/lymphoma patients following allogeneic hematopoietic stem cell transplantation. [J Immunol] Abstract A Natural-Like Synthetic Small Molecule Impairs Bcr-Abl Signaling Cascades and Induces Megakaryocyte Differentiation in Erythroleukemia Cells Some newly-shaped small molecules showed antiproliferative, pro-apoptotic and differentiating activity in leukemia cell lines. To investigate more in depth the mechanisms of action of these molecules, the protein expression profiles of K562 cells treated with or without the compounds IND_S1, MEL_T1, IND_S7 and MEL_S3 were analyzed using two-dimensional gel electrophoresis coupled with mass spectrometry. [PLoS One] Full Article Combining Dasatinib with Dexamethasone Longterm Leads to Maintenance of Anti-Viral and Anti-Leukemia Specific Cytotoxic T Cell Responses In Vitro The authors evaluated combination effects of dasatinib and dexamethasone on CD3+ and virus-specific CD8+ T cells directly ex vivo as well as on antigen-specific leukemia- and allo-reactive CD8+ T cell clones. [Exp Hematol] Abstract Mutation of the NPM1 Gene Contributes to the Development of Donor Cell-Derived Acute Myeloid Leukemia after Unrelated Cord Blood Transplantation for Acute Lymphoblastic Leukemia Researchers report a new case of donor cell leukemia after unrelated cord blood transplantation in a 44-year-old woman diagnosed as having acute lymphoblastic leukemia with t(1;19) that developed acute myeloid leukemia with normal karyotype and nucleophosmin (NPM1) mutation in donor cells. [Hum Pathol] Abstract CLINICAL RESEARCH Two Dosing Regimens of Tosedostat in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (OPAL): A Randomized Open-Label Phase II Study Tosedostat is a novel oral aminopeptidase inhibitor with clinical activity in a previous Phase I/II study in elderly patients with relapsed or refractory acute myeloid leukemia. Researchers aimed to compare two dosing regimens of tosedostat. [Lancet Oncol] Abstract Rates of Peripheral Arterial Occlusive Disease in Patients with Chronic Myeloid Leukemia in the Chronic Phase Treated with Imatinib, Nilotinib, or Non-Tyrosine Kinase Therapy: A Retrospective Cohort Analysis The risk of developing peripheral arterial occlusive disease on tyrosine kinase inhibitor (TKI) therapy is unknown and causality has not been established. Patients with chronic phase chronic myeloid leukemia from three randomized Phase III studies were divided into three cohorts: no TKI, nilotinib, and imatinib. [Leukemia] Abstract |